普米克令舒联合孟鲁司特钠治疗支气管哮喘的临床疗效研究  

Clinical observation of pulmicort respules combined with montelukast sodium in the treatment of bronchial asthma

作　　者：黄永督 华扬斌 Huang Yongdu;Hua Yangbin(Traditional Chinese Medicine Hospital of Yingde City,Guangdong Province,Guangdong Yingde 513000)

机构地区：[1]广东省英德市中医院,广东英德513000

出　　处：《中国社区医师》2021年第13期30-31,共2页Chinese Community Doctors

摘　　要：目的:分析普米克令舒联合孟鲁司特钠治疗支气管哮喘的临床疗效。方法:2019年1月-2020年12月收治支气管哮喘患者58例,按治疗方式不同分为两组,各29例。对照组接受普米克令舒治疗;观察组接受普米克令舒联合孟鲁司特钠治疗。比较两组治疗效果。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。观察组治疗后炎性因子指标白介素(IL)-33、IL-17、IL-4水平均低于对照组,差异有统计学意义(P<0.05)。结论:采用普米克令舒联合孟鲁司特钠药物治疗支气管哮喘,可显著改善炎性指标水平,疗效更理想。Objective:To analyze the clinical efficacy of pulmicort respules combined with montelukast sodium in the treatment of bronchial asthma.Methods:From January 2019 to December 2020,58 patients with bronchial asthma were selected,they were divided into the two groups according to different treatment methods with 29 case in each group.The control group was treated with pulmicort respules.The observation group was treated with pulmicort respules combined with montelukast sodium.The therapeutic effects of the two groups were compared.Results:The total effective rate of the observation group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).The levels of inflammatory factors such as interleukin-33(IL-33),interleukin-17(IL-17)and interleukin-4(IL-4)in the observation group were lower than those in the control group after treatment,the differences were statistically significant(P<0.05).Conclusion:Pulmicort respules combined with montelukast sodium in the treatment of bronchial asthma can significantly improve the level of inflammatory indexes,and the curative effect is better.

关 键 词：支气管哮喘 孟鲁司特钠 普米克令舒 疗效 炎性因子 

分 类 号：R562.25[医药卫生—呼吸系统]